- Home
- DATS vs PHIO Comparison
DATS vs PHIO Comparison
Compare DATS & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DATS
- PHIO
- Stock Information
- Founded
- DATS 2014
- PHIO 2011
- Country
- DATS United States
- PHIO United States
- Employees
- DATS N/A
- PHIO N/A
- Industry
- DATS Computer Software: Prepackaged Software
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- DATS Technology
- PHIO Health Care
- Exchange
- DATS Nasdaq
- PHIO Nasdaq
- Market Cap
- DATS 10.4M
- PHIO 8.6M
- IPO Year
- DATS 2021
- PHIO N/A
- Fundamental
- Price
- DATS $2.60
- PHIO $2.16
- Analyst Decision
- DATS
- PHIO Strong Buy
- Analyst Count
- DATS 0
- PHIO 2
- Target Price
- DATS N/A
- PHIO $9.00
- AVG Volume (30 Days)
- DATS 373.1K
- PHIO 703.0K
- Earning Date
- DATS 08-13-2025
- PHIO 08-13-2025
- Dividend Yield
- DATS N/A
- PHIO N/A
- EPS Growth
- DATS N/A
- PHIO N/A
- EPS
- DATS N/A
- PHIO N/A
- Revenue
- DATS $388.00
- PHIO N/A
- Revenue This Year
- DATS N/A
- PHIO N/A
- Revenue Next Year
- DATS N/A
- PHIO N/A
- P/E Ratio
- DATS N/A
- PHIO N/A
- Revenue Growth
- DATS N/A
- PHIO N/A
- 52 Week Low
- DATS $1.01
- PHIO $0.97
- 52 Week High
- DATS $9.34
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- DATS 48.99
- PHIO 50.19
- Support Level
- DATS $2.54
- PHIO $2.11
- Resistance Level
- DATS $2.80
- PHIO $2.30
- Average True Range (ATR)
- DATS 0.26
- PHIO 0.21
- MACD
- DATS -0.02
- PHIO -0.04
- Stochastic Oscillator
- DATS 12.39
- PHIO 9.65
About DATS DatChat Inc.
DatChat Inc is a blockchain, cybersecurity, and social media company that not only focuses on protecting privacy on personal devices, but also protects user information after it is shared with others. Its mobile messaging application is called DatChat Messenger which is a free messaging application. The platform allows users to exercise control over their messages and posts.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.